¿Qué hay de nuevo en el tratamiento de amiloidosis por cadenas livianas? Parte 1: cadenas livianas

Bendelman, Gisela; Carretero, Marcelina; Pérez de Arenaza, Diego; Villanueva, Eugenia; Brulc, Erika B; Nucifora, Elsa M; Marco, María A; Sáez, María S; Sorroche, Patricia B; Aguirre, María A; Posadas Martínez, María L.
Rev. Hosp. Ital. B. Aires (En línea) ; 43(4): 214-218, dic. 2023.
Artículo en Español | LILACS, UNISALUD, BINACIS | ID: biblio-1537605

Documentos relacionados

  1. CAR-T cells for the treatment of relapsed/refractory multiple myeloma in 2022: efficacy and toxicity.
  2. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
  3. [Optimization of treatment strategy for relapsed or refractory multiple myeloma].
  4. [Clinical development of chimeric antigen receptor T-cell therapy in multiple myeloma].
  5. Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
  6. B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages.
  7. Daratumumab in AL amyloidosis.
  8. Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature.
  9. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
  10. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.